Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx
Filed with ASX · · 2 pages · English
Story so far
Earlier from Imugene
- Response to ASX Query
- Research partnership with Celularity for solid tumors
- Prospectus for SPP and Placement Options Offer
- Imugene completes $90 M placement and launches $5 M SPP
- Appendix 4C - Quarterly Report
Later from Imugene
- Appendix 4E and Full Year Statutory Accounts
- Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials
- S&P DJI Announces September 2021 Quarterly Rebalance
- Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
- First patient dosed in Phase I clinical trial of CHECKvacc
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene